Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today commented on anticipated first quarter performance and updated its 2013 outlook for the Company.
Based upon recent communications with customers, Spectrum Pharmaceuticals anticipates a change in ordering patterns of FUSILEV
following the recent stabilization of the folate analog market. The Company now expects that FUSILEV sales will be approximately $10 to $15 million for the first quarter of the year, and approximately $80 to $90 million for the 2013 fiscal year. The Company noted that, while hospital sales are shifting to generics, the end-user demand for FUSILEV remains stable in the clinics, and the Company continues to anticipate solid demand in this segment in 2013. The Company believes the majority of the impact from the change in ordering patterns will be reflected in the first half of 2013 and expects to return to a run-rate that more closely aligns with end-user demand by the end of the year. The Company also expects its hematology franchise, which includes FOLOTYN
, to grow in 2013. Spectrum Pharmaceuticals anticipates total company revenues in the range of $160 to $180 million for the full-year 2013. The Company continues to manage operating expenses and expects to be profitable in 2013 on a non-GAAP basis.
Spectrum Pharmaceuticals is a growth-oriented leader in the acquisition, development and commercialization of oncology/hematology drug products. In addition to the Company’s portfolio of commercialized drugs, Spectrum Pharmaceuticals has opportunities to drive growth through the advancement of its late-stage pipeline, as well as potential acquisitions of new products. The Company expects to file its NDA for belinostat around the middle of 2013 and anticipates potential commercialization in 2014, subject to FDA approval. Spectrum Pharmaceuticals also anticipates that it will file an NDA for apaziquone in 2014.